American Society of Hematology articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2014/12/19 19:42
2014/12/19 19:42
1d
One of the most exciting companies in biotech just had one of the year’s most exciting initial public offerings. Shares of Seattle-based Juno Therapeutics increased 60% from their listing price to...
2014/12/19 19:42
2014/12/19 19:42
Latest videos
2014/12/17 22:59
2014/12/17 22:59
3d
Joining a record-breaking 26,000 hematologists and healthcare professionals who attended the recent 56th American Society of Hematology Annual Meeting and Exposition in San Francisco, Ca. were 12...
2014/12/15 20:16
2014/12/15 20:16
5d
Self-reported quality of life among patients diagnosed with aggressive lymphoma can predict overall survival and event-free survival, a Mayo Clinic study has found. The results were presented at the...
2014/12/12 12:17
2014/12/12 12:17
9d
NEW YORK--(BUSINESS WIRE)--During an investor and analyst meeting hosted today in New York, BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to...
2014/12/11 12:17
2014/12/11 12:17
10d
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports that interim data from a Phase I/II...
2014/12/11 10:42
2014/12/11 10:42
10d
At first glance, it’s hard to get excited about the preliminary results of an early phase trial study of pembrolizumab (Keytruda, MK-3475) in women with triple-negative breast cancer (TNBC). The...
2014/12/11 05:18
2014/12/11 05:18
10d
CHESHIRE, Connecticut--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) gab heute bekannt, dass Studienergebnisse, die zu einem besseren Verständnis des atypischen hämolytisch-urämischen...
2014/12/11 00:28
2014/12/11 00:28
10d
Bluebird Bio was the next winner. It develops gene therapies to treat individuals born with genetic diseases. It has great things in the pipeline, such as a treatment for sickle cell anemia that could...
2014/12/10 22:38
2014/12/10 22:38
10d
Maggie and Andy Oberhofer had discussed hospice options for their ailing baby less than a year ago when the prognosis seemed grim, but today the couple is figuring out how to re-baby proof their home...
2014/12/10 13:08
2014/12/10 13:08
10d
Study associates poor neurocognitive outcomes with variations in genes related to brain inflammation and oxidative stress, highlight potential interventions Common variations in four genes related to...
2014/12/09 15:42
2014/12/09 15:42
11d
The study, led by Srdan Verstovsek, M.D., Ph.D., professor of leukemia at The University of Texas MD Anderson Cancer Center, showed the compound was well tolerated in observing 27 patients....
2014/12/09 13:08
2014/12/09 13:08
11d
Novartis today announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi® (ruxolitinib), supporting the safety profile and efficacy benefit as measured in primary...
2014/12/09 12:49
2014/12/09 12:49
11d
SAN FRANCISCO—Four patients with a lethal blood disorder were able to forgo life-sustaining blood transfusions within 90 days after they were treated with a technique to replace the defective gene...
2014/12/09 11:17
2014/12/09 11:17
12d
SÃO FRANCISCO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) e Takeda Pharmaceutical Company Limited (TSE:4502) relataram hoje os dados que demonstram que os pacientes com linfoma de Hodgkin...
2014/12/09 11:08
2014/12/09 11:08
12d
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially...
2014/12/09 09:08
2014/12/09 09:08
12d
New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that...
2014/12/09 08:17
2014/12/09 08:17
12d
New data demonstrate that a five-minute infusion of the investigational specific antidote idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa®...
2014/12/09 06:08
2014/12/09 06:08
12d
Amgen (NASDAQ: AMGN) today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO™ (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute...
2014/12/09 03:08
2014/12/09 03:08
12d
Studies presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in...
2014/12/09 02:17
2014/12/09 02:17
12d
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data that continue to advance the understanding of atypical hemolytic uremic...
2014/12/19 19:42
2014/12/19 19:42
Latest from Twitter